CAR T-Cells That Fight Ovarian and Prostate Cancer by Targeting LHR
This patent describes a new type of CAR T-cell therapy designed to fight ovarian and prostate cancers by specifically targeting the Luteinizing Hormone Receptor (LHR) protein found on cancer cells.
Original patent title: “Car t-cell therapy directed to lhr for the treatment of solid tumors”
This patent describes a new type of CAR T-cell therapy designed to fight ovarian and prostate cancers by specifically targeting the Luteinizing Hormone Receptor (LHR) protein found on cancer cells. Owned by University of Southern California with 22 claims, and it is expected to expire in 2044.
Coverage
What does this patent actually cover?
This patent describes a Chimeric Antigen Receptor (CAR) that specifically targets the Luteinizing Hormone Receptor (LHR) protein. This CAR is made up of several parts: an "antigen binding domain" from an anti-LHR antibody (using specific heavy and light chain variable regions, like SEQ ID NO.: 3 and 7), a "hinge domain," a "transmembrane domain," a "costimulatory signaling region," and a "CD3 zeta signaling domain" (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). These CARs are then put into immune cells, typically T-cells or Natural Killer (NK) cells (Claim 8), making them into a targeted therapy. When these modified T-cells or NK cells encounter cancer cells that have LHR on their surface, they are designed to attack and inhibit the growth of those cancer cells (Claim 11, 13). For example, a patient with prostate cancer that expresses LHR could receive these modified T-cells to specifically target and destroy their tumor cells.
The gap
What does this patent NOT cover?
- CAR T-cell therapies that target cancer proteins other than the Luteinizing Hormone Receptor (LHR).
- CAR T-cells that do not include all the specified components, such as a hinge domain, transmembrane domain, costimulatory signaling region, and CD3 zeta signaling domain.
- CAR T-cells where the antigen binding domain does not use the specific antibody sequences (SEQ ID NO.: 3 and 7) or sequences with at least 90% identity to them.
- Methods of treating cancers that do not express or overexpress the LHR protein.
- Traditional chemotherapy, radiation therapy, or surgical methods for cancer treatment.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever bit is identifying and validating the Luteinizing Hormone Receptor (LHR) as a specific and effective target for CAR T-cell therapy in solid tumors like ovarian and prostate cancer. This patent provides the precise genetic blueprints (specific antibody sequences) needed to engineer T-cells to recognize and attack LHR-expressing cancer cells.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Kymriah (Novartis, a CAR T-cell therapy for blood cancers)
Yescarta (Gilead, a CAR T-cell therapy for blood cancers)
Prostate cancer treatments
Ovarian cancer treatments
Antibody-drug conjugates (another form of targeted therapy)
Why it matters
The bigger picture
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of certain blood cancers, but treating solid tumors like ovarian and prostate cancer remains a significant challenge. This patent focuses on a novel approach to target LHR, a protein found on some solid tumor cells, potentially opening new avenues for treatment. By providing specific antibody sequences, it lays a foundation for developing precise immunotherapies against these hard-to-treat cancers.
Filed
May 20, 2024
Market context
Who's building on this
Companies in this space
Major pharmaceutical companies like Novartis, Gilead Sciences, and Bristol Myers Squibb are leading the development of CAR T-cell therapies for various cancers. Academic institutions, including the University of Southern California (the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →), continue to conduct foundational research into new CAR targets and engineering methods. Many biotech startups are also actively exploring novel CAR designs and targets for solid tumors.
Market impact
CAR T-cell therapies have already created a new, multi-billion dollar market segment for hematological cancers. If successful, therapies targeting LHR in solid tumors could significantly expand this market, offering new treatment options for patients with ovarian and prostate cancers. This could lead to new clinical trials, regulatory approvals, and potentially shift treatment paradigms for these difficult-to-treat diseases, attracting substantial investment and competition in the oncology space.
Claim 1 — Plain English
What this patent covers
This patent describes a Chimeric Antigen Receptor (CAR) that specifically targets the Luteinizing Hormone Receptor (LHR) protein. This CAR is made up of several parts: an "antigen binding domain" from an anti-LHR antibody (using specific heavy and light chain variable regions, like SEQ ID NO.: 3 and 7), a "hinge domain," a "transmembrane domain," a "costimulatory signaling region," and a "CD3 zeta signaling domain" (Claim 1). These CARs are then put into immune cells, typically T-cells or Natural Killer (NK) cells (Claim 8), making them into a targeted therapy. When these modified T-cells or NK cells encounter cancer cells that have LHR on their surface, they are designed to attack and inhibit the growth of those cancer cells (Claim 11, 13). For example, a patient with prostate cancer that expresses LHR could receive these modified T-cells to specifically target and destroy their tumor cells.
The clever bit
The clever bit is identifying and validating the Luteinizing Hormone Receptor (LHR) as a specific and effective target for CAR T-cell therapy in solid tumors like ovarian and prostate cancer. This patent provides the precise genetic blueprints (specific antibody sequences) needed to engineer T-cells to recognize and attack LHR-expressing cancer cells.
What it does not cover
- CAR T-cell therapies that target cancer proteins other than the Luteinizing Hormone Receptor (LHR).
- CAR T-cells that do not include all the specified components, such as a hinge domain, transmembrane domain, costimulatory signaling region, and CD3 zeta signaling domain.
- CAR T-cells where the antigen binding domain does not use the specific antibody sequences (SEQ ID NO.: 3 and 7) or sequences with at least 90% identity to them.
- Methods of treating cancers that do not express or overexpress the LHR protein.
- Traditional chemotherapy, radiation therapy, or surgical methods for cancer treatment.
Patent timeline
Application submitted to the patent office
Patent enters public domain
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
15/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
0/20
Older than 20 years
Assignee scale
20/20
Major company or institution
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$59K – $187K
Midpoint $117K · 17.5 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
22 claims as filed with the patent office.
Concepts involved
Cite this patent
Epstein, A. L., Hu, P., & Pinski, J. K. CAR T-Cells That Fight Ovarian and Prostate Cancer by Targeting LHR (U.S. Patent No. 20,250,129,171). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20250129171/car-t-cell-therapy-directed-to-lhr-for-the-treatment-of-solid-tumors
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US20250129171"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 9328156 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Attack Cancer
US 20240165159 · Purdue Research Foundation
Targeting Cancer with CAR T Cells Using a Chemical Tag
US 9481728 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Fight CD19 Cancers
US 12600775 · 2026 · Kite Pharma
Treating a Specific Lymphoma with Modified T Cells
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does CAR T-Cells That Fight Ovarian and Prostate Cancer by Targeting LHR cover?
This patent describes a new type of CAR T-cell therapy designed to fight ovarian and prostate cancers by specifically targeting the Luteinizing Hormone Receptor (LHR) protein found on cancer cells.
Who owns patent US 20250129171?
This patent is owned by University of Southern California.
When does this patent expire?
This patent is expected to expire on May 20, 2044, when the invention enters the public domain.
What problem does this patent solve?
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of certain blood cancers, but treating solid tumors like ovarian and prostate cancer remains a significant challenge. This patent focuses on a novel approach to target LHR, a protein found on some solid tumor cells, potentially opening new avenues for treatment. By providing specific antibody sequences, it lays a foundation for developing precise immunotherapies against these hard-to-treat cancers.
What does this patent NOT cover?
CAR T-cell therapies that target cancer proteins other than the Luteinizing Hormone Receptor (LHR).
Patent monitoring





